Guardant Health Unveils Groundbreaking Study on Molecular Residual Disease in Colon Cancer

On February 2, 2026, Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, announced the publication of a landmark study that sets a new standard in the detection of molecular residual disease (MRD) in stage III colon cancer. This significant research, in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, is now available in the *Journal of Clinical Oncology* and showcases the potential of the Guardant Reveal® blood test in predicting cancer recurrence more accurately than traditional methods.

The study is the largest of its kind, analyzing circulating tumor DNA (ctDNA) in over 2,000 patients who underwent surgery for stage III colon cancer. Notably, it was found that approximately 20% of these patients exhibited detectable ctDNA in their blood following surgery. The implications are profound: those identified with ctDNA by the Guardant Reveal test faced a four-to-six-fold increase in the likelihood of experiencing disease recurrence or reduced survival rates compared to patients without detectable ctDNA.

Furthermore, even patients with smaller tumors or fewer affected lymph nodes, typically deemed lower risk through standard staging, exhibited over a six-fold higher risk of recurrence if ctDNA was present. This highlights the critical role that ctDNA testing could play in refining postoperative management, enabling healthcare providers to identify high-risk patients who may benefit from enhanced surveillance or alternative treatment strategies.

Dr. Frank Sinicrope, professor of oncology and medicine at Mayo Clinic and principal investigator for the study, emphasized the transformative potential of ctDNA testing. “The data suggest that not only the presence of ctDNA, but the amount of ctDNA, as identified by Guardant Reveal, may help refine risk beyond standard TNM staging,” he stated. This nuanced understanding of a patient’s risk profile could lead to more personalized adjuvant treatment recommendations and follow-up protocols.

Dr. Craig Eagle, Chief Medical Officer at Guardant Health, echoed these sentiments, remarking, “This large study adds to growing evidence that ctDNA testing with Guardant Reveal after surgery helps answer the question patients care about most: *Am I really cancer-free?*” He underscored the importance of personalizing post-surgical care to better guide treatment decisions.

The study's findings not only reinforce the clinical utility of Guardant Reveal in MRD detection but also signal the company's broader ambitions. Recently, Guardant has expanded the capabilities of Reveal to monitor therapy responses in late-stage cancers, thereby enhancing its application in assessing treatment effectiveness across a range of solid tumors. This approach aligns with earlier studies in early-stage breast cancer, further establishing Reveal’s versatility in identifying patients at elevated risk for recurrence.

Guardant Health’s recent press release underscores a pivotal advancement in the precision oncology landscape, particularly for stage III colon cancer patients. The evidence supporting ctDNA testing as a critical component of postoperative care could revolutionize how clinicians approach treatment decisions, offering hope for improved outcomes and tailored strategies based on individual patient risk profiles. As Guardant Health continues to innovate within the oncology space, the integration of cutting-edge technologies like the Guardant Reveal test promises to enhance patient care and potentially extend lives in the ongoing battle against cancer.